Multidisciplinary Perspectives for Alzheimer's and Parkinson's Diseases: Hydrogels for Protein Delivery and Cell-Based Drug Delivery as Therapeutic Strategies
Restricted accessReview articleFirst published online December, 2009
Multidisciplinary Perspectives for Alzheimer's and Parkinson's Diseases: Hydrogels for Protein Delivery and Cell-Based Drug Delivery as Therapeutic Strategies
This review presents two intriguing multidisciplinary strategies that might make the difference in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. The first proposed strategy is based on the controlled delivery of recombinant proteins known to play a key role in these neurodegenerative disorders that are released in situ by optimized polymer-based systems. The second strategy is the use of engineered cells, encapsulated and delivered in situ by suitable polymer-based systems, that act as drug reservoirs and allow the delivery of selected molecules to be used in the treatment of Alzheimer's and Parkinson's diseases. In both these scenarios, the design and development of optimized polymer-based drug delivery and cell housing systems for central nervous system applications represent a key requirement. Materials science provides suitable hydrogel-based tools to be optimized together with suitably designed recombinant proteins or drug delivering-cells that, once in situ, can provide an effective treatment for these neurodegenerative disorders. In this scenario, only interdisciplinary research that fully integrates biology, biochemistry, medicine and materials science can provide a springboard for the development of suitable therapeutic tools, not only for the treatment of Alzheimer's and Parkinson's diseases but also, prospectively, for a wide range of severe neurodegenerative disorders.
PopovicN., BrundinP.. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.Int J Pharm2006; 314: 120–6.
2.
FournierE., PassiraniC., Montero-MeneiC.N., BenoitJ.R.Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility.Biomaterials2003; 24: 3311–31.
3.
StabenfeldtS.E., GarciaA.J., LaPlacaM.C.. Thermoreversible laminin-functionalized hydrogel for neural tissue engineering.J Biomed Mater Res A2006; 77: 718–25.
4.
ZhongY., BellamkondaR.V.. Biomaterials for the central nervous system.J R Soc Interface2008; 5: 957–75.
5.
PeraleG., BiancoF., GiordanoC., MatteoliM., MasiM., CigadaA.. Engineering injured spinal cord with bone marrow-derived stem cells and hydrogel-based matrices: a glance at the state of the art.Journal of Applied Biomaterials & Biomechanics2008; 6: 1–8.
6.
MahoneyM.J., AnsethK.S.. Three-dimensional growth and function of neural tissue in degradable polyethylene glycol hydrogels.Biomaterials2006; 27: 2265–74.
7.
RileyM.C., FuegyP.W., FirpoM.A., ShuX.Z., PrestwichG.D., PeattieR.A.. Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels.Biomaterials2006; 27: 5935–43.
8.
KulkarniR.V., BiswanathS.A.. Electrically responsive smart hydrogels in drug delivery: a review.Journal of Applied Biomaterials & Biomechanics2007; 5: 125–39.
9.
TateM.C., ShearD.A., HoffmanS.W., SteinD.G., LaPlacaM.C.. Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury.Biomaterials2001; 22: 1113–23.
10.
GuptaD., TatorC.H., ShoichetM.S.. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord.Biomaterials2006; 27: 2370–9.
11.
HamannM.C.J., TatorC.H., ShoichetM.S.. Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord.Exp Neurol2005; 194: 106–19.
12.
HamannM.C.J., TsaiE.C., TatorC.H., ShoichetM.S.. Novel intrathecal delivery system for treatment of spinal cord injury.Exp Neurol2003; 182: 300–9.
13.
ChungC., MesaJ., MillerG.J., RandolphM.A., GillT.J., BurdickJ.A.. Effects of auricular chondrocyte expansion on neocartilage formation in photocrosslinked hyaluronic acid networks.Tissue Eng2006; 12: 2665–73.
14.
ChungC., MesaJ., RandolphM.A., YaremchukM., BurdickJ.A.. Influence of gel properties on neocartilage formation by auricular chondrocytes photoencapsulated in hyaluronic acid networks.J Biomed Mater Res A2006, 77A: 518–25.
15.
PeattieR.A., RiekeE.R., HewettE.M., FisherR.J., ShuX.Z., PrestwichG.D.. Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants.Biomaterials2006; 27: 1868–75.
HouS., XuQ., TianW.. The repair of brain lesion by implantation of hyaluronic acid hydrogels modified with laminin.J Neurosci Methods2005; 148: 60–70.
18.
CuiF.Z., TianW.M., HouS.P., XuQ.Y., LeeI.S.. Hyaluronic acid hydrogel immobilized with RGD peptides for brain tissue engineering.J Mater Sci: Mater Med2006; 17: 1393–401.
19.
BalgudeA.P., YuX., SzymanskiA., BellamkondaR.V.. Agarose gel stiffness determines rate of DRG neurite extension in 3D cultures.Biomaterials2001; 22: 1077–84.
20.
MauckR.L., SoltzM.A., WangC.C.. Functional tissue engineering of articular cartilage through dynamic loading of chondrocyte-seeded agarose gels.J Biomech Eng2000; 122: 252–60.
21.
KatzJ.S., BurdickJ.A.. Hydrogel mediated delivery of throphic factors for neural repair.Wiley Interdiscip Nanomed Nano-biotechnol2009; 1: 128–39.
22.
JainA., KimY.T., McKeonR.J., BellamkondaR.V.. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury.Biomaterials2006, 27: 497–504.
YuX., DillonG.P., BellamkondaR.V.. A laminin and nerve growth factor-laden three-dimensional scaffold for enhanced neurite extension.Tissue Eng1999; 5: 291–304.
25.
GilbertR.J., McKeonR.J., DarrA., CalabroA., HascallV.C., BellamkondaR.V.. CS-4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite extension.Mol Cell Neurosci2005; 29: 545–8.
26.
DodlaM.C., BellamkondaR.V.. Anisotropic scaffolds facilitate enhanced neurite extension in vitro.J Biomed Mater Res A2006; 78A: 213–21.
27.
HoffmanA.S.. Hydrogels for biomedical applications.Adv Drug Deliv Rev2002; 54: 3–12.
28.
HeC.L., KimS.W., LeeD.S.. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery.J Control Release2008; 127: 189–207.
29.
ChungH.J., ParkT.G.. Self-assembled and nanostructured hydrogels for drug delivery and tissue engineering.Nano Today2009; 4: 429–37.
30.
NguyenK.T., WestJ.L.. Photopolymerizable hydrogels for tissue engineering applications.Biomaterials2002; 23: 4307–14.
31.
YoonJ.J., ChungH.J., LeeH.J., ParkT.G.. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor.J Biomed Mater Res2006; 79: 934–42.
32.
BrizzolaraD., CantowH.J., DiederichsK., KellerE., DombA.J.. Mechanism of the stereocomplex formation between enantiomeric poly(lactide)s.Macromolecules1996; 29: 191–7.
ShimW.S., YooJ.S., BaeY.H., LeeD.S.. Novel injectable pH and temperature sensitive block copolymer hydrogel.Biomacromolecules2005; 6: 2930–4.
35.
DankersP.Y., HarmsenM.C., BrouwerL.A., van LuynM.J., MeijerE.W.. A modular and supramolecular approach to bioactive scaffolds for tissue engineering.Nat Mater2005; 4: 568–74.
36.
FuscoS., BorzacchielloA., NettiP.A.. Perspectives on PEO-PPO-PEO triblock copolymers and their biomedical applications.J Bioact Compat Polym2006; 21: 149–64.
PochanD.J., SchneiderJ.P., KretsingerJ., OzbasB., RajagopalK., HainesL.. Thermally reversible hydrogels via intramolecular folding and consequent self-assembly of a de Novo designed peptide.J Am Chem Soc2003; 125: 11802–3.
39.
NuttelmanC.R., RiceM.A., RydholmA.E., SalinasC.N., ShahD.N., AnsethK.S.. Macromolecular monomers for the synthesis of hydrogel niches and their application in cell encapsulation and tissue engineering.Prog Polym Sci2008; 33: 167–79.
40.
WangC., StewartR.J., KopecekJ.. Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein do-mains.Nature1999; 397: 417–20.
41.
ChenL., KopecekJ., StewartR.J.. Responsive hybrid hydrogels with volume transitions modulated by a titin immunoglobulin module.Bioconjug Chem2000; 11: 734–40.
42.
DoveA.. Cell-based therapies go live.Nat Biotechnol2002; 20: 339–43.
43.
SchmidtJ.J., RowleyJ., KongH.J.. Hydrogels used for cell-based drug delivery.J Biomed Mater Res A2008; 87A: 1113–22.
44.
LimF., SunA.M.. Microencapsulated islets as bioartificial endocrine pancreas.Science1980; 210: 908–10.
45.
AebischerP., WahlbergL., TrescoP.A., WinnS.R.. Macroencapsulation of dopamine-secreting cells by coextrusion with an organic polymer-solution.Biomaterials1991; 12: 50–6.
46.
ReadT.A., SorensenD.R., MahesparanR.. Local endostatin treatment of gliomas administered by microencapsulated producer cells.Nat Biotechnol2001; 19: 29–34.
47.
JokiT., MachlufM., AtalaA.. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy.Nat Biotechnol2001; 19: 35–9.
48.
OriveG., De CastroM., PonceS.. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules.Mol Ther2005; 12: 283–9.
49.
EmerichD.F., WinnS.R., HarperJ., HammangJ.P., BaetgeE.E., KordowerJ.H.. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons.J Comp Neurol1994; 349: 14864.
50.
SaitohY., TakiT., AritaN., OhnishiT., HayakawaT.. Cell therapy with encapsulated xenogeneic tumor-cells secreting betaendorphin for treatment of peripheral pain.Cell Transplant1995; 4: 13–7.
51.
WeberL.M., HaydaK.N., HaskinsK., AnsethK.S.. The effects of cell-matrix interactions on encapsulated beta-cell function within hydrogels functionalized with matrix-derived adhesive peptides.Biomaterials2007; 28: 3004–11.
52.
ChangT.M.S.. Therapeutic applications of polymeric artificial cells.Nat Rev Drug Discov2005; 4: 221–35.
53.
GugerliR., CantanaE., HeinzenC., Von StockarU., MarisonI.W.. Quantitative study of the production and properties of alginate/poly-L-lysine microcapsules.J Microencapsul2002; 19: 571–90.
54.
KhademhosseiniA., EngG., YehJ.. Micromolding of photocrosslinkable hyaluronic acid for cell encapsulation and entrapment.J Biomed Mater Res A2006; 79: 522–32.
55.
WeberL.M., HeJ., BradleyB., HaskinsK., AnsethK.S.. PEG based hydrogels as an in vitro encapsulation platform for testing controlled beta-cell microenvironments.Acta Biomater2006; 2: 1–8.
56.
AltomareL., FarèS.. Cells response to topographic and chemical micropatterns.Journal of Applied Biomaterials & Biomechanics2008; 6: 132–43.
57.
StokolsS., TuszynskiM.H.. Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal growth following spinal cord injury.Biomaterials2006; 27: 443–51.
58.
BrooksA.E., BrothersT.J., CreagerM.S., LewisR.V.. A novel methodology to explore the viscoelasticity of spider major ampullate silk.Journal of Applied Biomaterials & Biomechanics2007; 5: 158–65.
StokolsS., TuszynskiM.H.. The fabrication and characterization of linearly oriented nerve guidance scaffolds for spinal cord injury.Biomaterials2004; 25: 5839–46.
61.
CampbellJ.J., BaderD.L., LeeD.A.. Mechanical loading modulates intracellular calcium signaling in human mesenchymal stem cells.Journal of Applied Biomaterials & Biomechanics2008; 6: 9–15.
62.
GodaT., IshiharaK.. Soft contact lens biomaterials from bio-inspired phospholipid polymers.Expert Rev Med Devices2006; 3: 167–74.
63.
CatauroM., RaucciM.G., AusanioG., AmbrosioL.. Sol-gel synthesis, characterization and bioactivity of poly(ether-imide)/ TiO2 hybrid materials.Journal of Applied Biomaterials & Biomechanics2007; 5: 41–4.
64.
MishraR.K., SinghalJ.P., DattM., BanthiaA.K.. Amidated pectin based hydrogels: synthesis, characterization and cytocompatibility study.Journal of Applied Biomaterials & Biomechanics2007; 5: 88–94.
65.
OralE., PeppasN.A.. Hydrophilicmolecularly imprinted poly(hydroxyethyl-methacrylate) polymers.J Biomed Mater Res A2006; 78: 205–10.
66.
DraghiL., CigadaA.. Nanostructured surfaces for biomedical applications. Part I: nanotopography.Journal of Applied Biomaterials & Biomechanics2007; 5: 61–9.
67.
ForsgrenJ., SvahnF., JarmarT., EngqvistH.. Structural change of biomimetic hydroxyapatite coatings due to heat treatment.Journal of Applied Biomaterials & Biomechanics2007; 5: 23–7.
68.
KapurT.A., ShoichetM.S.. Immobilized concentration gradients of nerve growth factor guide neurite outgrowth.J Biomed Mater Res A2004; 68A: 235–43.
69.
GuarinoV., CausaF., AmbrosioL.. Porosity and mechanical properties relationship in PCL porous scaffolds.Journal of Applied Biomaterials & Biomechanics2007; 5: 149–57.
70.
PiotrowiczA., ShoichetM.S.. Nerve guidance channels as drug delivery vehicles.Biomaterials2006; 27: 2018–27.
71.
HaaparantaA.M., KoivurintaJ., HämääinenE.R., KellomäkiM.. The effect of cross-linking time on a porous freeze-dried collagen scaffold using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide as a cross-linker.Journal of Applied Biomaterials & Biomechanics2008; 6: 89–94.
72.
MorraM.. Advancements in carbohydrate bioactivity and implications for the surface modification of biomaterials.Journal of Applied Biomaterials & Biomechanics2007; 5: 1–10.
73.
MooreK., MacsweenM., ShoichetM.. Immobilized concentration gradients of neurotrophic factors guide neurite outgrowth of primary neurons in macroporous scaffolds.Tissue Eng2006; 12: 267–78.
74.
GiannoniP., NarcisiR.. Nano-approaches in cartilage repair.Journal of Applied Biomaterials & Biomechanics2009; 7: 1–12.
75.
GiordanoC., CausaF., BiancoF.. Gene delivery systems for gene therapy in tissue engineering and central nervous system applications.Int J Artif Organs2008; 31: 1017–26.
76.
GloriaA., RussoT., De SantisR., AmbrosioL.. 3D fiber deposition technique to make multifunctional and tailor-made scaffolds for tissue engineering applications.Journal of Applied Biomaterials & Biomechanics2009; 7: 141–52.
77.
BabaM., NakajoS., TuP.H.. Aggregation of alphasynuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.Am J Pathol1998; 152: 879–84.
78.
PankratzN., RoroudT.. Genetics of Parkinson disease.NeuroRx2004; 1: 235–42.
PolymeropoulosM.H., LavedanC., LeroyE.. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.Science1997; 276: 2045–7.
81.
KrugerR., KuhnW., MullerT.. Ala30Pro mutation in the gene encoding alpha–synuclein in Parkinson's disease.Nature Genet1998; 18: 106–8.
82.
ZarranzJ.J., AlegreJ., Gomez–EstebanJ.C., LezcanoE., RosR., AmpueroI.. The new mutation, E46K, of alpha–synuclein causes Parkinson and Lewy body dementia.Ann Neurol2004; 55: 164–73.
83.
KirikD., RosenbladC., BurgerC., LundbergC., JohansenT.E., MuzyczkaN., MandelR.J., BjorklundA.. Parkinson-like neurodegeneration induced by targeted overexpression of alpha–synuclein in the nigrostriatal system.J Neurosci2002; 22: 2780–91.
84.
WernigM., ZhaoJ.P., PruszakJ.. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.Proc Natl Acad Sci USA2008; 105: 5856–61.
PruszakJ., IsacsonO.. Molecular and cellular determinants for generating ES-cell derived dopamine neurons for cell therapy.Adv Exp Med Biol2009; 651: 112–23.
87.
SugayaK., MerchantS.. How to approach Alzheimer's disease therapy using stem cell technologies.J Alzheimers Dis2008; 15: 241–54.
Nakaji-HirabayashiT., KatoK., IwataH.. Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier.Biomaterials2009; 30: 4581–9.
90.
Nakaji-HirabayashiT., KatoK., IwataH.. Self-assembling chimeric protein for the construction of biodegradable hydrogels capable of interaction with integrins expressed on neural stem/progenitor cells.Biomacromolecules2008; 9: 1411–6.
91.
MoriyasuK., YamazoeH., IwataH.. Induction dopamine re-leasing cells from mouse embryonic stem cells and their long-term culture.J Biomed Mater Res A2006; 77: 136–47.
92.
ThonhoffJ.R., LouDl, JordanP.M., ZhaoX., WuP.. Compatibility of human fetal neural stem cells with hydrogel biomaterials in vitro.Brain Res2008; 1187: 42–51.
93.
BrännvallK., BergmanK., WallenquistU., SvahnS., BowdenT., HilbornJ., Forsberg-NilssonK.. Enhanced neuronal differentiation in a three-dimensional collagen-hyaluronan matrix.J Neurosci Res2007; 85: 2138–46.
94.
HolmesT.C., de LacalleS., SuX., LiuG.S., RichA., ZhangS.G.. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds.Proc Natl Acad Sci USA2000; 97: 6728–33.
95.
SilvaG.A., CzeislerC., NieceK.L.. Selective differentiation of neural progenitor cells by high-epitope density nanofibersScience2004; 303: 1352–5.
96.
WoerlyS., FortS., Pignot-PaintrandI., CottetC., CarcenacC., SavastaM.. Development of a sialic acid-containing hydrogel of poly (N-(2-hydroxypropyl) methacrylamide): characterization and implantation study.Biomacromolecules2008; 9: 2329–37.
97.
KatzmanT.. Senile dementia of the Alzheimer type.Ann Neurol1983; 14: 497–506.
98.
Grundke-lqbalI., IqbalK., TungY.C., QuinlanM., WisniewskiH.M., BinderL.I.. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.Proc Natl Acad Sci USA1986; 83: 4913–7.
99.
BleschA., LuP., TuszynskiM.H.. Neurotrophic factors, gene therapy, and neural stem cells for spinal cord repair.Brain Research Bulletin2002; 57: 833–8.
100.
ArevaloJ.C., WuS.H.. Neurotrophin signaling: many exciting surprises!Cell Mol Life Sci2006; 63: 1523–37.
101.
HarbaughR.E., SaundersR.L., ReederR.F.. Use of implantable pumps for central nervous-system drug infusions to treat neurological disease.Neurosurgery1988; 23: 693–8.
WhittleseyK.J., SheaL.D.. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface.Exp Neurol2004; 190: 1–16.
BurdickJ.A., WardM., LiangE., YoungM.J., LangerR.. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels.Biomaterials2006; 27: 452–9.
108.
DohJ., IrvineD.J.. Photogenerated polyelectrolyte bilayers from an aqueous-processible photoresist for multicomponent protein patterning.J Am Chem Soc2004; 126: 9170–1.
109.
KatzJ.S., DohJ., IrvineD.J.. Composition-tunable properties of amphiphilic comb copolymers containing protected methacrylic acid groups for multicomponent protein patterning.Langmuir2006, 22: 353–9.
110.
LuoY, ShoichetM.S.. A photolabile hydrogel for guided three-dimensional cell growth and migration.Nature Mater2004; 3: 249–53.
111.
LuoY, ShoichetM.S.. Light-activated immobilization of biomolecules to agarose hydrogels for controlled cellular response.Biomacromolecules2004; 5: 2315–23.
112.
Sakiyama-ElbertS.E., HubbellJ.A.. Controlled release of nerve growth factor from a heparin-containing fibrin based cell ingrowth matrix.J Control Release2000; 69: 149–58.
113.
TaylorS.J., McDonaldJ.W., Sakiyama-ElbertS.E.. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury.J Control Release2004; 98: 281–94.
114.
WillerthS.M., JohnsonP.J., MaxwellD.J.. Rationally designed peptides for controlled release of nerve growth factor from fibrin matrices.J Biomed Mater Res A2007; 80A: 13–23.
115.
GoraltchoukA., ScangaV., MorsheadC.M., ShoichetM.S.. In-corporation of protein-eluting microspheres into biodegradable nerve guidance channels for controlled release.J Control Release2006; 110: 400–7.
116.
MahoneyM.J., SaltzmanW.M.. Transplantation of brain cells assembled around a programmable synthetic microenvironment.Nature Biotechnol2001; 19: 934–9.
117.
WardM.S., KhoobehiA., LavikE.B., LangerR., YoungM.J.. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres.J Pharm Sci Technol2007; 96: 558–68.
118.
YuX.J., BellamkondaR.V.. Tissue-engineered scaffolds are effective alternatives to autografts for bridging peripheral nerve gaps.Tissue Eng2003; 9: 421–30.
119.
MerimsD., GiladiN.. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease.Parkinsonism Relat Disord2008; 14: 273–80.
120.
SudoJ., IwaseH., TeruiJ.. Transdermal absorption of L-dopafrom hydrogel in rats.Eur J Pharm Sci1998; 7: 67–71.
121.
SenthilkumarK.S., SaravananK.S., ChandraG., SindhuK.M., JayakrishnanA., MohanakumarK.P.. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.Brain Res2007; 184: 11–8.
122.
GaoP., XuH., DingP., GaoQ., SunJ., ChenD.. Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies.Int J Pharm2007; 330: 1–5.
123.
JoganiV.V., ShahP.J., MishraP., MishraA.K., MisraA.R.. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting.Alzheimer Dis Assoc Disord2008; 22: 116–24.
124.
SinghN., SeedatF., PillayV., SweetJ.L., DanckwertsM.P.. Formulation and statistical optimization of novel double-incorporated PLA-PLGA microparticles within an alginate-pectinate platform for the delivery of nicotine.J Microencapsul2006; 23: 153–67.
125.
AuluckP.K., ChanH.Y., TrojanowskiJ.Q., LeeV.M., BoniniN.M.. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.Science2002; 295: 865–8.
126.
AuluckP.K., MeulenerM.C., BoniniN.M.. Mechanisms of Sup-pression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila.J Biol Chem2005; 280: 2873–8.
127.
DongZ., WolferD.P., LippH.P., BüelerH.. Hsp70 gene transfer by adeno-associated virus inhibits MPTP induced nigrostriatal degeneration in the mouse model of Parkinson disease.Mol Ther2005; 11: 80–8.
128.
YangQ., SheH., GearingM., CollaE., LeeM., ShackaJ.J., MaoZ.. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy.Science2009; 323: 124–7.
NagelF., FalkenburgerB.H., TöngesL.. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease.J Neurochem2008; 105: 853–64.
131.
BatelliS., AlbaniD., RamettaR.. DJ-1 modulates alphasynuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.PLoS ONE2008; 3: e1884.
132.
BenaroudjN., FangB., TriniollesF., GhelisC., LadjimiM.M.. Overexpression in Escherichia coli, purificationand characterization of the molecular chaperone HSC70.Eur J Biochem1993; 93: 1566–73.
133.
JindalS., MurrayP., RosenbergS., YoungR.A., WilliamsK.P.. Human stress protein HSP70: overexpression in E. coli, purification and characterization.Biotechnology1995; 13: 1105–9.
134.
WadiaJ.S., DowdyS.F.. Transmembrane delivery of protein and peptide drugs by TATmediated transduction in the treatment of cancer.Adv Drug Deliv Rev2005; 57: 579–96.
135.
DietzG.P., BährM.. Delivery of bioactive molecules into the cell: the Trojan horse approach.Mol Cell Neurosci2004; 27: 85–131.
136.
SharpS., WorkmanP.. Inhibitors of the HSP90 molecular chaperone: current status.Adv Cancer Res2006; 95: 323–48.
137.
XiongM.P., YáñezJ.A., RemsbergC.M.. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats.J Control Rel2008; 129: 33–40.
138.
KwonH.M., KimY.J., RyuS., YangS.I., LeeS.H., YoonB.W.. Differential expression of HSP70 mRNA in the mouse brain after treatment with geldanamycin.Neurol Res2009; 31: 541–4.
139.
LeeJ., TanC.Y., LeeS.K., KimY.H., LeeK.Y.Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction.J Control Release2009; 137: 196–202.
140.
HemmingM.L., PattersonM., Reske-NielsenC., LinL., IsacsonO., SelkoeD.J.. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.PLoS Med2007; 4: e262.
141.
CapanY, JiangG., GiovagnoliS., NaK.H., DeLucaP.P.. Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone.AAPS PharmSciTech2003; 4: E28.
142.
ChenF., WuZ., WangQ., WuH., ZhangY., NieX., JinY.. Preparation and biological characteristics of recombinant human bone morphogenetic protein-2-loaded dextran-co-gelatin hydrogel microspheres, in vitro and in vivo studies.Pharmacology2005; 75: 133–44.
143.
AndreopoulosF.M., PersaudI.. Delivery of basic fibroblast growth factor (bFGF) from photoresponsive hydrogel scaffolds.Biomaterials2006; 27: 2468–76.
144.
Aubert-PouësselA., Venier-JulienneM.C., ClavreulA.. In vitro study of GDNF release from biodegradable PLGA microspheres.J Control Release2004; 95: 463–75.
145.
GuH., LongD., SongC., LiX.. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion.Neuroscience Lett2009; 453: 204–9.
146.
CamarataP.J., SuryanarayananR., TurnerD.A., ParkerR.G., EbnerT.J.. Sustained release of nerve growth factor from biodegradable polymer microspheres.Neurosurgery1992; 30: 313–9.
147.
KordowerJ.H., ChuY., HauserR.A., FreemanT.B., OlanowC.W.. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.Nature Med2008; 14: 504–6.
